Detection of Minimal Hepatic Encephalopathy in Iranian Patients with Cirrhosis

Mahsa Khodadoostan1, Sina Sadeghian2, Ali Safaei2

  • 1Assistant Professor of Gastroenterology and Hepatology, Department of Gastroenterology and Hepatology, AlZahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.

Insights

Minimal hepatic encephalopathy (MHE) affects 26.7% of cirrhosis patients, showing links to MELD score, Child class, and younger age. Men were more affected than women.

Area of Science:

  • Hepatology
  • Neurology
  • Clinical Medicine

Background:

  • Minimal hepatic encephalopathy (MHE) is the earliest stage of hepatic encephalopathy in cirrhosis patients.
  • MHE presents with subtle neurocognitive deficits despite normal clinical examinations, negatively impacting quality of life.
  • Identifying MHE and its contributing factors is crucial for managing cirrhosis complications.

Purpose of the Study:

  • To diagnose Minimal hepatic encephalopathy (MHE) in patients with cirrhosis.
  • To investigate factors associated with MHE in this population.

Main Methods:

  • A cross-sectional study involving 120 cirrhosis patients was conducted.
  • Cirrhosis severity was assessed using MELD (Model for End-stage Liver Disease) and Child-Pugh criteria.
  • The Psychometric Hepatic Encephalopathy Score (PHES) test was administered to diagnose MHE.

Main Results:

  • 26.7% of the studied cirrhosis patients were diagnosed with MHE.
  • MHE was significantly associated with higher MELD scores and advanced Child class.
  • Younger age and male gender were also significantly associated with MHE.
  • Patients with MHE were younger on average than those without MHE.

Conclusions:

  • Minimal hepatic encephalopathy (MHE) is prevalent in cirrhosis patients and linked to disease severity (MELD score, Child class).
  • Age and gender are notable factors associated with MHE, with younger males being more affected.
  • Further research is recommended to explore the reversible association of age with MHE and its implications.

Related Concept Videos

Types of Errors: Detection and Minimization01:12

Types of Errors: Detection and Minimization

Error is the deviation of the obtained result from the true, expected value or the estimated central value. Errors are expressed in absolute or relative terms.
Absolute error in a measurement is the numerical difference from the true or central value. Relative error is the ratio between absolute error and the true or central value, expressed as a percentage.
Errors can be classified by source, magnitude, and sign. There are three types of errors: systematic, random, and gross.
Systematic or...
10.9K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
266
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.6K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
221
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
543
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
305